-
Professor Jianyun Nie: Discussing Consensus and Controversies in Breast Cancer Diagnosis and Treatment in the South of Colorful Clouds
The 8th Yunling Breast Cancer Summit Forum, hosted by the Yunnan Anti-Cancer Association and the China Medical Education Association and organized by Peking University Cancer Hospital Yunnan Hospital/Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Center, Yunnan Breast Cancer Clinical Research Center, Yunnan Anti-Cancer Association Breast Cancer Professional Committee, Yunnan Medical Association…
-
Professor Guojun Zhang: Towering Yunling Mountains, Gathering of Renowned Experts, and Highlighting the New Heights of Breast Cancer Diagnosis
From July 12th to 14th, the 2024 CACA Integrated Breast Cancer Conference and The 8th Yunling Breast Cancer Summit Forum were held in Kunming, Yunnan. “Oncology Frontier” invited Professor Guojun Zhang, the chairman of both conferences and the president of Yunnan Cancer Hospital, to introduce the conference highlights, the hot directions of translational medicine research…
-
BOC/BOA 2024 | Professor Meng Wu: Major Advances in Lymphoma Treatment Boost Precision Medicine Development
From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. This conference focused on the “2023 Annual Progress in Clinical Oncology in China” selected by CSCO, aiming to deeply analyze the latest research achievements in the…
-
Expert Interview | Professor Victor Navarro: Management and Challenges of Drug-Induced Liver Injury in Oncology
In the journey of cancer treatment, drug-induced liver injury is a significant issue that cannot be overlooked. The “8th International Forum on Drug-Induced Liver Injury,” held on May 25, 2024, focused on the management of drug-induced liver injury caused by anticancer drugs, inviting numerous renowned experts and scholars from around the world for rich academic…
-
Clinical Characteristics and Treatment Strategies for Immune Checkpoint Inhibitor-Induced Liver Injury
Recently, the “8th International Forum on Drug-Induced Liver Injury and the 9th National Conference on Drug-Induced Liver Injury” along withthe release of the 2024 primary care version of “Chinese Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury” was held in the beautiful city of Xiamen. The theme of this conference focused on the…
-
CDM Monthly Review
Greetings to all experts and colleagues. In this issue of the CDM Monthly Review, we will share six recent articles in the field of portal hypertension diagnosis and treatment (four on diagnostic monitoring and two on multidisciplinary treatment). This issue features reviews by invited experts: Professor Pengyuan He from the Center for Infectious Disease Control…
-
BOC/BOA 2024丨Professor Chaosu Hu: Advances in Immunotherapy and Proton Carbon Ion Therapy for Head and Neck Tumors
Traditional treatment for head and neck tumors mainly involves surgery, radiotherapy, and chemotherapy. In recent years, immune checkpoint inhibitors have shown promising potential in treating head and neck squamous cell carcinoma, and new radiotherapy techniques such as proton and carbon ion therapy offer treatment options with reduced radiation toxicity for patients with head and neck…
-
Professor Uwe Platzbecker: Breakthrough Progress in the Treatment of Acute Promyelocytic Leukemia (APL) — Key Findings from the APOLLO Study
Acute promyelocytic leukemia (APL) is a highly aggressive blood disorder, and its treatment has always been a challenge in the field of hematology. Chinese scholars have contributed the arsenic trioxide (ATO) regimen for global APL patients. Since the APL0406 study reported in the New England Journal of Medicine in 2013, all-trans retinoic acid (ATRA) combined…
Connecting Medical Expertise through Media